Although much remains unknown about the role of CD6 in T-cell activation, the new data from human autoimmune disease databases and experimental systems argue for testing anti-CD6 as a therapy for the treatment of a wide range of autoimmune syndromes, specifically those that are mediated by Th1 and Th17 cells. Here, CD6 is linked to autoimmune disease.